Oguz Melahat Melek, Oguz Ayse Deniz, Sanli Cihat, Cevik Ayhan
Department of Pediatric Cardiology, Gazi University Medical School, 06065 Ankara, Turkey.
Tex Heart Inst J. 2014 Apr 1;41(2):159-64. doi: 10.14503/THIJ-12-3012. eCollection 2014 Apr.
This prospective cross-sectional study attempted to determine both the usefulness of the serum intercellular adhesion molecule-1 (ICAM-1) as a biomarker for pulmonary artery hypertension secondary to congenital heart disease and the nature of this marker's association with catheter angiographic findings. Our study included a total of 70 male and female children, comprising 30 patients with both pulmonary artery hypertension and congenital heart disease, 20 patients with congenital heart disease alone, and 20 healthy control subjects. Levels of ICAM-1 in plasma samples from all groups were measured by the enzyme-linked immunosorbent assay method. Cardiac catheterization was also performed in all patients. The mean serum ICAM-1 levels in pediatric patients who had congenital heart disease with and without pulmonary artery hypertension were 349.6 ± 72.9 ng/mL and 312.3 ± 69.5 ng/mL, respectively (P=0.002). In healthy control subjects, the mean serum ICAM-1 level was 231.4 ± 60.4 ng/mL. According to the results of this study, the ICAM-1 level of the pulmonary artery hypertension group was significantly higher than those of the congenital heart disease group and the healthy control group. Correlation analysis showed that ICAM-1 level was correlated with systolic and mean pulmonary artery pressures (r=0.62, P=0.001; r=0.57, P=0.001)-which are 2 important values used in diagnosis of pulmonary artery hypertension. Moreover, receiver operating characteristic analysis yielded consistent results for the prediction of pulmonary artery hypertension. Therefore, we conclude that ICAM-1 has potential use as a biomarker for the diagnosis and follow-up of pulmonary artery hypertension.
这项前瞻性横断面研究试图确定血清细胞间黏附分子-1（ICAM-1）作为先天性心脏病继发肺动脉高压生物标志物的有用性，以及该标志物与导管血管造影结果之间关联的性质。我们的研究共纳入70名男性和女性儿童，其中包括30名患有肺动脉高压和先天性心脏病的患者、20名单纯患有先天性心脏病的患者以及20名健康对照者。采用酶联免疫吸附测定法测量所有组血浆样本中的ICAM-1水平。所有患者均进行了心导管检查。患有先天性心脏病且伴有和不伴有肺动脉高压的儿科患者的血清ICAM-1平均水平分别为349.6±72.9 ng/mL和312.3±69.5 ng/mL（P = 0.002）。在健康对照者中，血清ICAM-1平均水平为231.4±60.4 ng/mL。根据本研究结果，肺动脉高压组的ICAM-1水平显著高于先天性心脏病组和健康对照组。相关性分析表明，ICAM-1水平与收缩期和平均肺动脉压相关（r = 0.62，P = 0.001；r = 0.57，P = 0.001），这是用于诊断肺动脉高压的两个重要数值。此外，受试者工作特征分析在预测肺动脉高压方面得出了一致的结果。因此，我们得出结论，ICAM-1有潜力作为肺动脉高压诊断和随访的生物标志物。
